ANIKHIGH SIGNALFINANCIAL10-K

ANIK achieved a substantial improvement in net losses alongside reduced operating expenses, though gross profit declined meaningfully year-over-year.

The dramatic improvement in bottom-line performance suggests either successful cost management or resolution of prior-year charges, representing a significant operational turnaround. However, the 16% decline in gross profit indicates potential headwinds in core business performance that investors should monitor closely.

Comparing 2026-03-03 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

ANIK demonstrated substantially improved profitability with net losses narrowing considerably from the prior year, supported by an 11.6% reduction in SG&A expenses and modest debt reduction. However, gross profit declined 16%, suggesting pressure on core business margins or revenue mix. The company also reduced inventory levels by 21% and continued share repurchases, indicating active balance sheet management during this transitional period.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+80.7%
-$56.4M-$10.9M

Net income grew 80.7% — bottom-line growth signals improving overall business health.

Inventory
Balance Sheet
-21.1%
$23.8M$18.8M

Inventory reduced 21.1% — lean inventory management or demand outpacing supply.

Gross Profit
P&L
-16%
$76.0M$63.8M

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Total Debt
Balance Sheet
-14.3%
$11.2M$9.6M

Debt reduced 14.3% — deleveraging strengthens balance sheet and reduces financial risk.

Share Buybacks
Cash Flow
-13.1%
$10.9M$9.5M

Buyback activity reduced 13.1% — capital being redeployed elsewhere or cash conservation underway.

SG&A Expense
P&L
-11.6%
$55.6M$49.1M

SG&A reduced 11.6% — improved cost efficiency or headcount reduction improving operating margins.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-17
ADDED
At February 20, 2026, there were 13,400,751 shares of the registrant s common stock outstanding.
Our license agreements with Johnson Johnson MedTech ( J J MedTech ) provide substantial control of Monovisc and Orthovisc in the United States to J J MedTech, and J J MedTech s actions could have a material impact on our business, financial condition and results of operations.
Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.
Anika s Mission: Together, we restore active living and redefine what s possible with hyaluronic acid.
Anika s Core Values: Trust and Respect: We build trust and show respect in every interaction.
+7 more — sign up free →
REMOVED
At March 6, 2025, there were 14,175,994 shares of the registrant s common stock outstanding.
Our license agreements with Johnson Johnson MedTech ( J J MedTech ) (previously known as DePuy Synthes Mitek Sports Medicine) provide substantial control of Monovisc and Orthovisc in the United States to J J MedTech, and J J MedTech s actions could have a material impact on our business, financial condition and results of operations.
The activities involved with our recent divestitures could disrupt our ongoing business, distract our management and increase our expenses.
Anika s Mission: Powered by our passionate team, we partner with clinicians to create and provide meaningful advancements in early intervention orthopedic care.
We are unwavering in our commitment to quality and compliance as we develop and commercialize solutions that restore active living for people around the world.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →